# Combination Therapy for BRAF-V600E Metastatic CRCm

> **NCT06411600** · PHASE2 · RECRUITING · sponsor: **Vall d'Hebron Institute of Oncology** · enrollment: 94 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Encorafenib
- **DRUG:** Cetuximab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06411600
- **Lead sponsor:** Vall d'Hebron Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-17
- **Primary completion:** 2027-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411600, "Combination Therapy for BRAF-V600E Metastatic CRCm". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06411600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*